Myriad Genetics reported companion diagnostics revenues of $2 million for its fiscal fourth-quarter compared to none the year before, a result of its $80 million purchase this spring of protein biomarker firm Rules-Based Medicine (PM 04/28/2011). Its total revenues for the fourth quarter were $107.4 million, up 14 percent from $93.9 million a year ago.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.